Bullish Outlook on Vigil Neuroscience Inc. Amid Promising Clinical Data and Unique TREM2 Biology Focus

view original post

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating on November 8. Don’t Miss our Black Friday Offers: Unlock your investing potential …